Publications by authors named "M P Siakantaris"
Background: Primary cutaneous B-cell lymphomas (PCBCLs) are rare cutaneous neoplasms with limited literature regarding treatment options and associated treatment outcomes. This study aimed to investigate and present real-world treatment outcomes in patients with PCBCLs.
Methods: All patients with PCBCL who were treated in five major referral centers for cutaneous lymphoma in Greece over 10 years were retrospectively included with their baseline characteristics and treatment-associated outcomes collected and analyzed.
Article Synopsis
- - The study analyzed the effectiveness and safety of methotrexate (MTX) in treating mycosis fungoides (MF) across different stages, involving 211 patients from five Greek centers, with a median age of 68.3 years.
- - Results showed an overall response rate of 55.5%, with better outcomes in patients receiving MTX as a first-line treatment and those with erythrodermic disease compared to tumor stage disease.
- - The study concludes that MTX is a viable first-line treatment option for MF, demonstrating varying progression-free survival rates depending on the disease stage and acceptable safety profiles.
Monitoring Humoral Response Following BNT162b2 mRNA Vaccination against SARS-CoV-2 in Hematopoietic Stem-Cell Transplantation Patients: A Single-Center Prospective Study along with a Brief Review of Current Literature.
Hematol Rep
April 2024
Article Synopsis
- A study evaluated the antibody response (AR) in 54 hematopoietic stem-cell transplantation (HSCT) recipients after receiving the BNT162b2 vaccine, showing an initial AR positivity rate of 80.8% at one month, which slightly decreased to 85.7% at three months.
- Among the cohort, a significant number of participants achieved high antibody titers at both measurement points, but a noted decline in titers occurred from one month to three months post-vaccination.
- Negative factors impacting AR included pre-treatment conditions like hypogammaglobulinemia and specific medications like anti-CD20 antibodies, suggesting HSCT patients can benefit from vaccination around six months post-transplant even in the
Prognostic Impact of Serum β-Microglobulin Levels in Hodgkin Lymphoma Treated with ABVD or Equivalent Regimens: A Comprehensive Analysis of 915 Patients.
Cancers (Basel)
January 2024
The significance of serum beta-2 microglobulin (sβm) in Hodgkin lymphoma (HL) is controversial. We analyzed 915 patients with HL, who were treated with ABVD or equivalent regimens with or without radiotherapy. Sβm levels were measured by a radioimmunoassay (upper normal limit 2.
View Article and Find Full Text PDF